Pzifer – Immunotherapy in Urothelial Carcinoma – RFP

Pfizer Global Medical Grants (GMG), and Merck KGaA, Darmstadt, Germany – Global Medical Unit Oncology are collaborating to provide grant support for continuing professional education in the area of Immuno-Oncology. Immuno-Oncology is a top priority for Merck KGaA, Darmstadt, Germany and Pfizer Inc, and for the Global Strategic Alliance between our organizations.

This publicly posted Request for Proposal (RFP) provides details regarding a general area of interest, sets timelines for review and approval, and uses an internal company-alliance review process to make final grant decisions. Organizations are invited to submit an application addressing the knowledge gaps as outlined in the RFP.

For all independent medical education grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, and conduct of the independent initiative supported by the grant. Our companies must not be involved in any aspect of project development, nor the conduct of the independent education program.

Geographic Scope: Europe, Asia, Latin America, Canada; Global if primary focus is on one of these areas

Clinical Area: Oncology – Genitourinary – Urothelial Carcinoma

Link to full RFP: Immunotherapy in Urothelial Carcinoma

Application Due Date: February 23, 2023

Specific Area of Interest: The intent of this RFP is to support independent education initiatives for healthcare professionals involved in the treatment of patients with locally-advanced or metastatic urothelial carcinoma (mUC), including oncologists, urologists, and specialty nurses.